Bridging the German gap

Evotec AG's purchase of Bionamics GmbH gives it access to a collection of autoimmune assets sourced from German universities. The move is the latest in a series of steps taken by Evotec to build a pipeline of new university-generated assets to complement its fee-for-service operations.

The move returns Bionamics CEO Timm Jessen to Evotec in the new position of EVP of business development in charge of EVT Innovate, the business segment that houses the biotech's translational projects and additional discovery partnerships...